Maha Katabi - 19 Sep 2023 Form 4 Insider Report for RayzeBio, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 19 Sep 2023
Net transaction value: +$8,499,996
SEC form: 4
Accepted by SEC: 21 Sep 2023, 17:10:06 UTC
Prior SEC filing: 14 Sep 2023
Next SEC filing: 17 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Jeff Woodley, Attorney-in-fact

Key filing fact

Maha Katabi filed Form 4 for RayzeBio, Inc. on 21 Sep 2023.

Key facts

This page summarizes Maha Katabi's Form 4 filing for RayzeBio, Inc..
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 21 Sep 2023, 17:10.

Change

Previous filing in this sequence was filed on 14 Sep 2023.
Current net transaction value: +$8,499,996.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RYZB transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +973,653
Change %
Price
Shares after: 973,653
Date: 19 Sep 2023
Ownership: See footnote
Footnotes: F1, F2

RYZB transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +973,653
Change %
Price
Shares after: 973,653
Date: 19 Sep 2023
Ownership: See footnote
Footnotes: F1, F3

RYZB transaction

Common Stock

Purchase

Transaction value: $4,249,998
Shares: +236,111
Change %: +24%
Price: $18.00^*
Shares after: 1,209,764
Date: 19 Sep 2023
Ownership: See footnote
Footnotes: F2, F4

RYZB transaction

Common Stock

Purchase

Transaction value: $4,249,998
Shares: +236,111
Change %: +24%
Price: $18.00^*
Shares after: 1,209,764
Date: 19 Sep 2023
Ownership: See footnote
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYZB transaction Derivative

Series D Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -973,653
Change %: -100%
Price
Shares after: 0
Date: 19 Sep 2023
Ownership: By Sofinnova Venture Partners X, L.P.
Underlying class: Common Stock
Underlying amount: 973,653
Exercise price
Footnotes: F1, F2

RYZB transaction Derivative

Series D Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -973,653
Change %: -100%
Price
Shares after: 0
Date: 19 Sep 2023
Ownership: By Sofinnova Venture Partners XI, L.P.
Underlying class: Common Stock
Underlying amount: 973,653
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Every 5.141 shares of Series D Convertible Preferred Stock (the "Preferred Stock") automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

Footnote F2

The shares are held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.P. ("SM X LP"), the general partner of SVP X, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management X-A, L.L.C. ("SM X LLC"), the general partner of SM X LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM X LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.

Footnote F3

The shares are held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP"), the general partner of SVP XI, may be deemed to have sole voting and dispositive power over these shares, and Sofinnova Management XI, L.L.C. ("SM XI LLC"), the general partner of SM XI LP, may be deemed to have sole voting and dispositive power over these shares. Dr. James I. Healy and Dr. Maha Katabi, the managing members of SM XI LLC, may be deemed to have shared power to vote and dispose of these shares. Such entities and individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.

Footnote F4

The shares were purchased in the Issuer's initial public offering.